University Hospital Zurich, Division of Pulmonology, Zurich, Switzerland.
University of Zurich, Faculty of Medicine, Zurich, Switzerland.
Int J Chron Obstruct Pulmon Dis. 2021 Jan 28;16:167-177. doi: 10.2147/COPD.S286360. eCollection 2021.
Combined pulmonary fibrosis and emphysema (CPFE) is an underrecognized syndrome characterized by chronic, progressive disease with a dismal prognosis. Frequent co-morbidities with a higher incidence than in idiopathic pulmonary fibrosis or emphysema alone are pulmonary hypertension (WHO group 3) in 47-90% of the patients and lung cancer in 46.8% of the patients.
Review current evidence and knowledge concerning diagnosis, risk factors, disease evolution and treatment options of CPFE.
We searched studies reporting CPFE in original papers, observational studies, case reports, and meta-analyses published between 1990 and August 2020, in the PubMed, Embase, Cochrane Library, Wiley Online Library databases and Google Scholar using the search terms [CPFE], [pulmonary fibrosis] OR [IPF] AND [emphysema]. Bibliographies of retrieved articles were searched as well. Further inclusion criteria were publications in English, French, German and Italian, with reference to humans. In vitro data and animal data were not considered unless they were mentioned in studies reporting predominantly human data.
Between May 1, 1990, and September 1, 2020, we found 16 studies on CPFE from the online sources and bibliographies. A total of 890 patients are described in the literature. Although male/female ratio was not reported in all studies, the large majority of patients were male (at least 78%), most of them were current or former heavy smokers.
CPFE is a syndrome presenting with dyspnea on exertion followed by disruptive cough and recurrent exacerbations. The disease may progress rapidly, be aggravated by pulmonary hypertension WHO group 3 and is associated with an increased risk of lung cancer. Smoking and male sex are important risk factors. There is a need for more research on CPFE especially relating to etiology, influence of genetics, treatment and prevention options. Antifibrotic therapy might be an interesting treatment option for these patients.
合并性肺纤维化和肺气肿(CPFE)是一种未被充分认识的综合征,其特征为慢性、进行性疾病,预后较差。与特发性肺纤维化或肺气肿单独相比,CPFE 患者常合并多种疾病,发病率更高,其中肺动脉高压(WHO 第 3 组)占 47-90%,肺癌占 46.8%。
综述 CPFE 的诊断、危险因素、疾病演变和治疗选择的当前证据和知识。
我们检索了 1990 年至 2020 年 8 月间发表的报告 CPFE 的原始论文、观察性研究、病例报告和荟萃分析,在 PubMed、Embase、Cochrane 图书馆、Wiley Online Library 数据库和 Google Scholar 中使用搜索词[CPFE]、[肺纤维化]或[特发性肺纤维化]和[肺气肿]。还检索了检索到的文章的参考文献。进一步的纳入标准是发表在英语、法语、德语和意大利语的出版物,涉及人类。除非在主要报告人类数据的研究中提到,否则不在考虑范围之内的体外数据和动物数据。
2020 年 9 月 1 日,我们从在线资源和参考文献中找到了 16 项关于 CPFE 的研究。文献中描述了 890 例患者。尽管并非所有研究都报告了男女比例,但绝大多数患者为男性(至少 78%),大多数患者为现吸烟者或曾吸烟者。
CPFE 是一种以运动性呼吸困难为表现的综合征,随后出现破坏性咳嗽和反复恶化。疾病可能迅速进展,被 WHO 第 3 组肺动脉高压加重,并与肺癌风险增加相关。吸烟和男性是重要的危险因素。需要对 CPFE 进行更多的研究,特别是与病因学、遗传学的影响、治疗和预防选择有关。抗纤维化治疗可能是这些患者的一个有趣的治疗选择。